CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31,…
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient…
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…
- Study demonstrates alpha-synuclein biomarker can be detected in 93-100% of patients with clinically defined pathologies using simple skin biopsy…
DALLAS, TX and MARTINSRIED, GERMANY / ACCESSWIRE / March 20, 2024 / Celanese Corporation (NYSE:CE), a global specialty materials and…
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territorySAN FRANCISCO,…
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target…
Encourages industry-wide trial transformation to improve data accuracy and incorporate AI-driven insights.DANA POINT, CA / ACCESSWIRE / March 20, 2024…
New open-source dataset aims to help pharmaceutical companies provide faster, more accurate responses to healthcare provider inquiries about drugsSAN FRANCISCO,…
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”),…